A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures

PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Specific DNA a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:NPJ Precis Oncol
Päätekijät: Diossy, Miklos, Sztupinszki, Zsofia, Borcsok, Judit, Krzystanek, Marcin, Tisza, Viktoria, Spisak, Sandor, Rusz, Orsolya, Timar, Jozsef, Csabai, István, Fillinger, Janos, Moldvay, Judit, Pedersen, Anders Gorm, Szuts, David, Szallasi, Zoltan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8213828/
https://ncbi.nlm.nih.gov/pubmed/34145376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00199-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia